Employees: 1,712
Size Contec Medical Systems (300869.SZ) is a China Health Care company (Medical Specialties) with a market value of $547M, the 3475th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.15 on 18 Nov 2026.
Performance Over six months the shares fell 25.9%, against -13.7% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 19 in its peer set.
Growth Revenue fell 2.5% over the last twelve months (peer median +8.7%); the operating margin is -16.1% (peer median 2.2%).
Valuation It trades at 5.5× enterprise value to sales against a peer median of 4.6× (8th most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is -20%, so the hurdle is +35 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 13.3 points below its cost of capital (6.8% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥478M | CN¥464M | CN¥476M | CN¥737M | CN¥706M |
| Revenue growth | — | -2% | -36% | +5% | — |
| Gross profit | CN¥212M | CN¥210M | CN¥222M | CN¥408M | CN¥321M |
| EBITDA | n/a | -CN¥26.0M | -CN¥89.5M | CN¥137M | CN¥123M |
| Net income | -CN¥91.1M | -CN¥24.4M | -CN¥77.9M | CN¥166M | CN¥196M |
| Free cash flow | CN¥71.1M | CN¥25.1M | CN¥126M | CN¥258M | CN¥44.3M |
| Capital expenditure | CN¥23.5M | CN¥49.5M | CN¥54.5M | CN¥30.7M | CN¥81.4M |
| Total debt | CN¥810M | CN¥967M | CN¥787M | CN¥1.05B | CN¥1.58B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300869.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.8% | -4.3% | 5th lowest of 19 |
| 6-month return | -25.9% | -13.7% | 7th lowest of 19 |
| Distance from 52-week high | -49.5% | -34.3% | 6th lowest of 20 |
| Revenue growth (TTM) | -2.5% | +8.7% | 7th lowest of 20 |
| Operating margin | -16.1% | 2.2% | 6th lowest of 20 |
| EV / Sales | 5.5× | 4.6× | 8th most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 15.0% | 7.2% | 2nd most demanding of 7 |
| Growth delivered (Del g) | -19.8% | -0.6% | lowest of 7 |
| Hurdle (Req g minus delivered) | +34.8 pp | +8.7 pp | 2nd most demanding of 7 |
| ROIC minus cost of capital | -13.3 pp | -1.3 pp | 5th lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Contec Medical Systems 300869.SZ | China | $547M | -26% | -2% | -16% | 5.5× | 15.0% | -19.8% |
| Zhejiang Gongdong Medical Technology 605369.SS | China | $542M | -21% | +6% | 9% | 2.6× | 10.2% | +6.5% |
| Cowealth Medical China 603122.SS | China | $562M | -34% | -18% | -5% | 5.9× | n/a | n/a |
| Jin Medical International ZJYL | United States | $532M | +47% | -14% | 2% | 26.5× | n/a | n/a |
| Myriad Genetics MYGN | United States | $530M | +45% | -3% | -13% | 0.8× | n/a | n/a |
| Wuhan Huakang Century Clean Technology 301235.SZ | China | $563M | -57% | +28% | 7% | 1.6× | n/a | n/a |
| AVITA Medical RCEL | United States | $529M | +290% | +17% | -34% | 6.7× | n/a | n/a |
| Pacific Biosciences of California PACB | United States | $573M | +54% | +4% | -98% | 6.7× | n/a | n/a |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $575M | -38% | +6% | 8% | 3.3× | n/a | n/a |
| MedicalSystem Biotechnology 300439.SZ | China | $518M | -9% | +14% | 2% | 1.5× | 6.0% | -7.7% |
| Anbio Biotechnology NNNN | United States | $518M | -89% | +10% | 67% | n/a | n/a | n/a |
| Guangdong Hybribio Biotech 300639.SZ | China | $511M | -18% | -7% | 4% | 3.9× | 0.4% | -13.2% |
| Shofu 7979.T | Japan | $510M | +32% | +9% | 14% | 1.6× | n/a | n/a |
| Orchestra BioMed OBIO | United States | $587M | +87% | +1,007% | -195% | 18.3× | n/a | n/a |
| Anteris Technologies Global AVR | United States | $508M | -40% | +9% | -4,880% | 125.0× | n/a | n/a |
| Assure Tech (Hangzhou) 688075.SS | China | $508M | -27% | -9% | -8% | 5.4× | 30.8% | -18.6% |
| Ningbo David Medical Device 300314.SZ | China | $589M | +25% | +19% | 11% | 5.4× | n/a | n/a |
| Hangzhou AGS MedTech 688581.SS | China | $590M | -22% | -18% | 33% | 3.7× | 0.4% | +27.8% |
| Tactile Systems Technology TCMD | United States | $592M | +6% | +14% | 9% | 1.5× | 8.4% | +12.0% |
| vVARDIS VVVV | United States | $594M | n/a | +148% | -72% | 14.3× | n/a | n/a |
| Sahajanand Medical Technologies SMT.NS | India | $595M | n/a | n/a | n/a | n/a | n/a | n/a |